Since its FDA approval over 5 years ago, myfortic® has been prescribed for more than 13,000 renal transplant patients in the United States.
myfortic delivers efficacy and safety comparable with CellCept® in de novo and maintenance renal transplant patients.1-3
The incidence of principal adverse events reported for both agents in the pivotal clinical trials was also comparable.
Click here for complete prescribing information.
